Navigation Links
The Parkinson's Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinson's Disease
Date:10/10/2007

NEW YORK, Oct. 10 /PRNewswire-USNewswire/ -- To mark 50 years of service to the Parkinson's community, the Parkinson's Disease Foundation (PDF) will present an authoritative round-up of the state of Parkinson's research at a two-day symposium on Thursday, October 11 and Friday, October 12. The jam-packed program will feature 43 top-notch Parkinson's professionals presenting the latest news in Parkinson's science and quality of life initiatives.

The meeting, entitled Frontiers of Science and Clinical Advances in Quality of Life, will be open to everyone touched by Parkinson's disease including researchers, clinicians, allied health professionals, people with Parkinson's and caregivers. It is being jointly sponsored by PDF and The Movement Disorders Society and will be held in the historic South Street Seaport district of lower Manhattan.

The Scientific Program Committee, led by PDF's Scientific Director, Stanley Fahn, M.D., the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University, will cover a wide range of topics including epidemiology, biomarkers for PD, neuroprotection and gene therapy. "This is going to be a comprehensive review of where we have been and where we are going in Parkinson's research, presented by premier neuroscientists in the field," said Dr. Fahn.

The Clinical Advances in Quality of Life Program Committee is led by Lucien Cte, M.D., Professor of Neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of Neurology at Columbia University. "With a disease like Parkinson's, where everyone's case is unique, it is crucial to realize how it affects day-to-day living. These are the issues that we are going to focus on, the issues that can make a real difference in the way a person lives," said Dr. Cte. Specifically, sessions will focus on the preclinical diagnosis of Parkinson's disease; respiratory, gastrointestinal, urological and sexual issues; sleep disorders; caregiver support and the therapeutic effect of exercise.

A high point of the event will be the presentation, at a celebratory dinner following the first day's program, of the James Parkinson Award, PDF's highest honor, which is given only once each decade. This year, the award will go to Dr. Stanley Fahn, in recognition of his lifetime of achievement as a scientist and clinician in Parkinson's disease.

At the same reception, PDF will present a special 50th Anniversary Award for Exemplary Contributions to the Advancement of Parkinson's Science. The award will go jointly to Dr. Alim-Louis Benabid, Chairman of Neurosurgery at Joseph Fourier University in Grenoble, France, and Dr. Mahlon DeLong, Professor of Neurology at Emory University, for their pioneering work in developing deep brain stimulation (DBS) for Parkinson's disease.

PDF will also be recognizing Rhona Johnson with the very first Award for Leadership in Caregiving, an honor that will be presented by Lonnie Ali, wife and caregiver of Muhammad Ali. Ms. Johnson became involved with the Parkinson's community through the diagnosis of her now late husband Bob, in 1994, to whom she was sole caregiver.

Seats for the symposium are sold out; however, those who are not able to attend the event may view the symposium for free via webcast by visiting http://www.pdf.org/50th.

The symposium is made possible by our generous supporters: Boehringer Ingelheim Pharmaceuticals, Inc.; HealthShares, Inc.; Novartis Pharmaceuticals; UCB, Inc.; GlaxoSmithKline; Solvay Pharmaceuticals, Inc.; Carol and Melvin Taub and Family; Valeant Pharmaceuticals North America; The Avicena Group; IMPAX Pharmaceuticals, Inc.; Medtronic, Inc.; the Medtronic Foundation; PatientsLikeMe, Inc.; Sepracor; Solstice Neurosciences, Inc.; Teva Neuroscience; Vernalis Pharmaceuticals, Inc.; Biogen Idec; Ceregene, Inc.; GE Healthcare Financial Services; Kyowa Pharmaceutical, Inc.; and ParkinsonsCommunity.org.

About the Parkinson's Disease Foundation

The Parkinson's Disease Foundation (PDF) is a leading national presence in Parkinson's disease research, education and public advocacy. We are working for the nearly one million people in the US living with Parkinson's by funding promising scientific research and supporting people with Parkinson's, their families and caregivers through education programs and support services. Since our founding in 1957, PDF has funded over $70 million worth of scientific research in Parkinson's disease, supporting the work of leading scientists throughout the world.


'/>"/>
SOURCE Parkinson's Disease Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New PCR Primers for Human Diseases
2. Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System
3. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
4. Th1 and Th2 Balance, Regulation, and Involvement in Disease
5. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
6. Medical College receives $377K to study brain disease
7. Thompsons HHS legacy will include efforts to combat disease in Africa
8. Stem cells produce anti-disease protein in brain experiment
9. Neurognostics pushes early prediction of brain disease
10. ZyStor receives first funding and buys theraputics for rare diseases
11. Predictive medicine: Genes indicate diseases before symptoms do
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):